NCT00871910 is a Phase 1 clinical trial of SCH 727965 in Solid Tumors, sponsored by Merck Sharp & Dohme LLC.

Who is sponsoring NCT00871910?

NCT00871910 is sponsored by Merck Sharp & Dohme LLC.

What drugs are being tested in NCT00871910?

Interventions in NCT00871910: SCH 727965, SCH 727965, SCH 727965, SCH 727965, Aprepitant, Ondansetron, Dexamethasone.

What condition does NCT00871910 study?

NCT00871910 studies Solid Tumors, Lymphoma, Non-Hodgkin, Multiple Myeloma.

Is NCT00871910 still recruiting?

NCT00871910 is currently completed. Last updated 23 October 2017.

Last reviewed 2017-10-23 · How we verify

NCT00871910

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)

Completed Phase 1 Last updated 23 October 2017

What this trial tests

Phase 1 trial testing SCH 727965 in Solid Tumors in 81 participants. Completed in 22 February 2010.

Timeline

11 October 2006

Primary endpoint
22 February 2010

22 February 2010

Quick facts

Lead sponsor	Merck Sharp & Dohme LLC
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	81
Start date	11 October 2006
Primary completion	22 February 2010
Estimated completion	22 February 2010

Drugs / interventions tested

SCH 727965 — full drug profile →
SCH 727965 — full drug profile →
SCH 727965 — full drug profile →
SCH 727965 — full drug profile →
Aprepitant (APREPITANT) — full drug profile →
Ondansetron (ondansetron) — full drug profile →
Dexamethasone (dexamethasone) — full drug profile →

Conditions studied

Solid Tumors — all drugs for Solid Tumors →
Lymphoma, Non-Hodgkin — all drugs for Lymphoma, Non-Hodgkin →
Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

Merck Sharp & Dohme LLC — full company profile →

Who can join

18 and older, any sex, with Solid Tumors or Lymphoma, Non-Hodgkin. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Part 1 and Part 2 of this trial will evaluate the safety, tolerability, maximum administered dose, and dose limiting toxicity of SCH 727965 administered every 3 weeks as a 2 hour intravenous (IV) infusion (Part 1), and as an 8-hour or 24-hour IV infusion (Part 2). Each 3-week period is considered one treatment cycle. Part 3 of this trial will evaluate the effect of coadministration of antiemetic drug aprepitant on the pharmacokinetics of SCH 727965 administered as a 2 hour IV infusion once every 3 weeks.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.
Mita MM, Mita AC, Moseley JL, Poon J, et al · · 2017 · cited 46× · PMID 28859059 · DOI 10.1038/bjc.2017.288
CDK9 inhibitors in multiple myeloma: a review of progress and perspectives.
Borowczak J, Szczerbowski K, Ahmadi N, Szylberg Ł. · · 2022 · cited 23× · PMID 35092513 · DOI 10.1007/s12032-021-01636-1
Enhancers in T Cell development and malignant lesions.
Zhang T, Zou L. · · 2024 · PMID 39284807 · DOI 10.1038/s41420-024-02160-7

Verify or expand the search:

Other recruiting trials for Solid Tumors

Currently open trials in the same condition.

NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors · recruiting
NCT07416123 — A Study of GEN1106 in Participants With Solid Tumors · Phase 1 · recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
NCT07395258 — A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Differe · Phase 1 · recruiting
NCT07505069 — Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors · EARLY_PHASE1 · recruiting

Other Merck Sharp & Dohme LLC trials

Trials by the same sponsor.

NCT07224477 — A Clinical Study of V540A in Healthy Female Participants (V540A-005) · Phase 2 · not yet recruiting
NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07528508 — A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527 · Phase 1 · not yet recruiting
NCT07513376 — A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (M · Phase 3 · not yet recruiting
NCT07532304 — A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Parti · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00871910 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Merck Sharp & Dohme LLC
Last refreshed: 23 October 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00871910.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing